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ABSTRACT
IL-18 polymorphisms influence the transcriptional activity of the IL-18 gene 
and associated with various diseases. However, their relationships with hepatitis B 
virus-related liver diseases had not reached a consensus. So we conducted this case-
control study with a view to clarifying the association. We included four groups: healthy 
controls, chronic hepatitis B virus (CHB) carriers, liver cirrhosis (LC) and hepatocellular 
carcinoma (HCC) groups with each group of 250 persons. Odd ratios (ORs) and 95% 
confidence intervals (95%CIs) with or without adjustment were calculated. Haplotype 
analysis was also performed. The results showed people carrying rs187238 CG genotype 
had a lower risk of LC (CG vs. CC: OR = 0.59, 95%CI = 0.38–0.91, P = 0.02), while 
GG genotype carriers had a higher risk of HCC (GG vs. CC+CG: OR = 4.73, 95%CI = 
1.01–22.1, P = 0.03) than those with CC and CG genotypes in healthy group. Rs187238 
GG genotype increased the risk from CHB to LC status (GG vs. CC: OR = 4.81, 95%CI = 
1.03–22.6; GG vs. CC+CG: OR = 4.73, 95%CI = 1.01–22.1), meanwhile the trend also 
existed by controlling confounding factors (GG vs. CC: OR = 6.25, 95%CI = 1.09–35.8; 
GG vs. CC+CG: OR = 5.91, 95%CI = 1.04–33.7). Haplotype Crs187238Trs1946518  
moderately decreased the risk of CHB carriers developing into HCC (OR = 0.69, 95%CI 
= 0.50–0.96, P = 0.03) after adjustment. In conclusion, IL-18 rs187238 GG genotype 
may increase the risk of HCC in healthy population and the risk of LC in CHB carriers.
INTRODUCTION
From 1990 to 2013, ranking of viral hepatitis on 
leading death causes worldwide rose from the tenth to 
seventh [1]. Despite the availability of an effective vaccine 
and antiviral approaches, more than 250 million people 
suffer from chronic hepatitis B (CHB) infection and nearly 
one million deaths occur each year owing to complications 
worldwide [2, 3]. Genomic mutations including drug-
resistant mutants and vaccine-escape mutants (G145R, 
G145A, F134L and others) hinder the treatment and 
prevention of hepatitis B virus (HBV) infection [2]. 
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Prospective studies revealed chronically infected HBV 
patients had an up to 100-fold increased risk for progressing 
to hepatocellular carcinoma (HCC) [4]. Genomic mutations 
were significantly involved in the development of HBV-
related HCC. P203Q and S210R which are mutations in 
HBsAg C-terminus hamper HBsAg-secretion and correlate 
with increased cellular proliferation and HBV-induced 
HCC [5]. A meta-analysis performed by Tian T et al. 
indicated that miR-146a C>G increased HBV-related HCC 
risk while miR-196a-2 C>T decreased the risk of HBV-
related HCC, especially in the Chinese population [6]. A 
retrospective study found the AG genotype and G allele 
for A3G rs8177832 polymorphism related to a decreased 
risk of CHB and HBV-related HCC and TT genotype of 
rs2011861 polymorphism confer to an increased risk of 
HBV-related HCC [7].
    Interleukin-18 (IL-18), firstly described as 
interferon (IFN)-gamma inducing factor, is one of the 
members of the IL-1 cytokine superfamily [8, 9]. IL-
18 modulates the Th1 response together with IL-12 to 
produce IFN-gamma [10]. It has been shown that IL-18 
can also influence Th2 response in synergy with other 
Th2-stimulating factors [11]. Thus, IL-18 is capable of 
increasing the activity of both Th1-type and Th2-type 
CD4+ T cells depending on its cytokine milieu [12]. CD4+ 
T cells can contribute directly to disease pathogenesis 
and inhibit viral replication during HBV infection [13]. 
Cytotoxic T lymphocytes can directly recognize and 
kill infected hepatocytes [14]. IL-18 plays a part in the 
clearance of viruses, partly by the induction of cytotoxic 
T cells [15]. All the findings suggest IL-18 may be 
associated with HBV and HCC. Human IL-18 gene is 
located on chromosome 11q22.2–22.3 and contains six 
exons. Within the promoter region of the IL-18 gene, two 
polymorphisms (rs187238 and rs1946518) have been 
identified, which influence the transcriptional activity of 
the IL-18 gene [16]. Previous studies demonstrated an 
significant association between rs1946518 polymorphism 
and various diseases risk, such as asthma, Crohn’s disease 
and breast cancer [17–19]. Rs1946518 polymorphism 
was also suggested to be associated with hepatitis C 
virus  (HCV) infections [20]. Hass SL et al. found though 
different genotypes of the two SNPs distributed equally 
in HCV patients and health controls, they were related 
to treatment response in hepatitis C patients [21]. Li Y et 
al. found no association between the two SNPs and HBV 
recurrence after liver transplantation in Chinese Han 
people [22].
   Several researches have studied the impact of the 
two polymorphisms on HBV-induced liver diseases, but 
no consistent conclusions had been achieved [23–26]. 
The purpose of this study was to assess the relationship 
of rs187238 and rs1946518 polymorphisms and the risk 
of HBV-liver cirrhosis (LC) and HBV-related HCC in the 
northwestern Chinese population.
RESULTS
Characteristics of the study population
The included subjects were equally categorized 
into four groups with 250 participants, healthy controls, 
CHB, CHB-positive LC and CHB-positive HCC (Table 1). 
The average (±standard deviation) of the four parts were 
55.71 ± 9.17, 54.17 ± 10.37, 53.12 ± 10.58 and 54.42 ± 
12.00, respectively. Males occupied 80.4%, 72.8%, 70.8% 
and 77.6% in the healthy group, CHB carriers, LC and 
HCC patients, respectively. The four groups did differ 
significantly in alcohol history (P = 0.002) and diabetes 
history (P = 0.021), while they had no meaningful 
difference in smoking history (P = 0.100) and family 
history (P = 0.647). Furthermore, patients carrying CHB 
related liver diseases had higher laboratory parameters 
than healthy controls, including T-Bil, ALT and AST levels 
(P <0.001), which are evidences of liver injury [27].
The alleles and genotype distributions of IL-
18 polymorphisms were shown in Table 2. Genotype 
frequencies of the two polymorphisms in control group 
were consistent with HWE (Table 3, rs187238: P = 0.142; 
rs1946518: P = 0.90). A LC patient and five HCC patients 
were failed to detect 187328 genotype, and three patients 
with HCC was failed to detect rs1946518 polymorphism. 
For rs187238 polymorphism, as displayed in Table 2, 
healthy controls with CC, CG and GG genotypes were 
183, 65 and 2; CHB carriers were 200, 48, and 2; LC 
patients were 202, 42 and 5, and HCC subjects were 187, 
49 and 9, respectively. For rs1946518 polymorphism, 
GG, GT and TT genotype accounts for 25.6%, 49.6% and 
24.8% in disease free controls, 24.4%, 53.6% and 22% in 
CHB carriers, 28.8%, 47.2% and 24% in LC patients, and 
26.8%, 47.2% and 24.8% in HCC patients, respectively 
(Table 2).
Association between IL-18 polymorphisms and 
the risk of LC
Compared with healthy people carrying rs187238 
CC genotype, people with CG genotype had a low risk of 
LC (Table 4, CG vs. CC: OR = 0.59, 95%CI = 0.38–0.91, 
P = 0.02). The genotype GG at187238 was more frequent 
in LC patients than CHB patients (2% vs. 0.8%) and 
logistic regression analyses showed a higher LC risk in 
CHB carriers with rs187238 GG genotype than individuals 
with CG or CC genotypes (GG vs. CC: OR = 6.25, 95%CI 
= 1.09–35.8; GG vs. CC+CG: OR = 5.91, 95%CI = 
1.04–33.7). However, after controlling for gender, age, 
smoking and alcohol consumption, the result indicated no 
significant difference in rs187238 polymorphism between 
LC and health controls (Table 5). No relationship between 
rs1946518 polymorphism and LC susceptibility was 
detected (Tables 4 and 5).
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Association between IL-18 polymorphisms and 
the risk of HCC 
A significant higher risk of HCC was associated with 
rs187238 GG genotype, when compared with healthy controls 
with CC/CG genotypes (Table 4, GG vs. CC+CG: OR = 4.73, 
95%CI = 1.01–22.1) and the similar trend was also observed 
after adjustment for gender, age, smoking and alcohol 
consumption (Table 5, GG vs. CC: OR = 6.96, 95%CI = 
1.24–39.0; GG vs. CC+CG: OR = 7.64, 95%CI = 1.37–42.5). 
Unfortunately, whether compared with healthy group or CHB 
carriers, rs1946518 polymorphism did not have a significant 
influence on developing to HCC (Tables 4 and 5).
Association between IL-18 polymorphisms and 
the risk from LC to HCC
Displayed in Table 5, neither of the two 
polymorphisms hampered or accelerated patients from 
LC progressing to HCC (Table 4). Adjusting for gender, 
age, smoking and drinking status did not have a meaning 
change (Table 5).
Haplotype distributions of IL-18 polymorphisms 
in healthy controls, HBV, LC and HCC patients 
We further performed the haplotype analyses 
to evaluate the haplotype frequencies of rs187238 
and rs1946518 polymorphisms. Three haplotypes 
(Grs187238Trs1946518, Crs187238Trs1946518 and Crs187238Grs1946518) were 
analyzed. As shown in Table 6, the two polymorphisms had 
no interaction. However, after adjustment by gender, age, 
smoking and drinking, haplotype Crs187238Trs1946518 moderately 
decreased the risk of CHB carriers developing into HCC 
(Table 7, OR = 0.69, 95%CI = 0.50–0.96, P = 0.03).
DISCUSSION
IL-18 promoter single-nucleotide polymorphisms 
(SNPs) were suggested to associate with different 
Table 1: Characteristics of included subjects
Characteristics Healthy 
controls
CHB CHB-related 
LC
CHB-related HCC P 
Total number 250 250 250 250
Age (mean ± SD) 55.71 ± 9.17 54.17 ± 10.37 53.12 ± 10.58 54.47 ± 12.00 0.056
Gender
Male 201 182 177 194 0.051
Female 49 68 73 56
Alcohol history
yes 22 53 39 42 0.002
no 228 197 211 208
Smoking history
yes 145 137 118 131 0.100
no 105 113 132 119
Diabetes history
Yes 22 30 39 44 0.021
no 228 220 211 206
Family history
Yes 8 7 12 10 0.647
No 242 243 238 240
Laboratory parameters
T-Bil level (umol/L) 8.49 ± 4.09 14.35 ± 5.29 39.22 ± 11.58 36.76 ± 10.11 < 0.001
ALT (U/L) 15.36 ± 5.27 65.33 ± 13.40 63.84 ± 21.26 71.03 ± 16.50 < 0.001
AST (U/L) 12.35 ± 4.05 49.62 ± 15.16 47.99 ± 24.83 58.21 ± 17.55 < 0.001
AFP (ng/ml) No data 7.94 ± 3.31 43.43 ± 29.46 1629.59 ± 625.28 < 0.001
Number of patients with 
AFP ≤400 ng/ml
− − − 156
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein.
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expression of IL-18 by causing differences in transcription 
factor binding [28]. Rs187238 polymorphism, which has 
a change from G to C changes the H4TF-1 nuclear factor 
binding site, while rs1946518 polymorphism disrupts 
a potential cAMP-responsive element binding protein 
binding site [16]. Furthermore, rs187238 polymorphism 
could affect significantly IL-18 transcriptional activity 
[29]. Rs1946518 polymorphism is highly linked with the 
pathogenesis of chronic C virus infection (HCV) and HCV-
infected patients had higher levels of IL-18 that correlate 
Table 2: Allele and genotype distributions of rs187238 and rs1946518 polymorphisms in healthy 
controls, CHB, LC and HCC patients
Model Control (n, %) CHB (n, %) LC (n, %) HCC (n, %)
rs187238   
Allele C 431 (86.2%) 448 (89.6%) 446 (89.6%) 423 (86.3%)
G 69 (13.8%) 52 (10.4%) 52 (10.4%) 67 (13.7%)
Codominant model CC 183 (73.2%) 200 (80%) 202 (81.1%) 187 (76.3%)
CG 65 (26%) 48 (19.2%) 42 (16.9%) 49 (20%)
GG 2 (0.8%) 2 (0.8%) 5 (2%) 9 (3.7%)
Dominant model CC 183  (73.2%) 200 (80%) 202 (81.1%) 187 (76.3%)
CG+GG 67 (26.8%) 50 (20%) 47 (18.9%) 58 (23.7%)
Recessive model CC+CG 248 (99.2%) 248(99.2%) 244 (98%) 236 (96.3%)
GG 2 (0.8%) 2 (0.8%) 5 (2%) 9 (3.7%)
rs1946518  
Allele G 252 (50.4%) 256 (51.2%) 262 (52.4%) 252 (51%)
T 248 (49.6%) 244 (48.8%) 238 (47.6%) 242 (49%)
Codominant model GG 64 (25.6%) 61 (24.4%) 72 (28.8%) 67 (27.1%)
GT 124 (49.6%) 134 (53.6%) 118 (47.2%) 118 (47.8%)
TT 62 (24.8%) 55 (22%) 60 (24%) 62 (25.1%)
Dominant model GG 64 (25.6%) 61 (24.4) 72 (28.8%) 67 (27.1%)
GT+TT 186 (74.4%) 189 (75.6%) 178 (71.2%) 180 (72.9%)
Recessive model GG+GT 188 (75.2%) 195 (78%) 190 (76%) 185 (74.9%)
TT 62 (24.8%) 55 (22%) 60 (24%) 62 (25.1%)
Haplotype GT 13.80% 10.40% 10.44% 13.52%
CT 35.80% 38.40% 36.95% 35.66%
CG 50.40% 51.20% 52.61% 50.82%
HWE = hardy-weinberg equilibrium, CHB = chronic hepatitis B, LC = liver cirrhosis, HCC = hepatocellular carcinoma, GT, 
Grs187238Trs1946518; CT, Crs187238Trs1946518; CG, Crs187238Grs1946518.
Table 3: Hardy-Weinberg equilibrium test for the rs187238 and rs1946518 polymorphisms in the 
control group
Observed frequency Expected frequency P
Rs187238
CC 183 185.761 0.142
CG 65 59.478
GG 2 4.761
Rs1946518
GG 64 63.504 0.900
GT 124 124.992
TT 62 61.504
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with disease severity [30]. The two polymorphisms were 
also related to susceptibility to various diseases, such as 
tuberculosis, type 1 diabetes, and CHB [31–33].
Recently, the association between the two 
polymorphisms (rs187238 and rs1946518 polymorphisms) 
and HBV-related liver diseases were frequently researched. 
Lau HK et al. included 559 healthy controls and 342 HCC 
patients to investigate the relationship and finally found 
rs187238 GC and CC genotypes not only increased the risk 
of HCC, but also was responsible for vascular invasion 
and enhanced the prognosis in HBV-related HCC [34]. 
Rs1946518 polymorphism was associated with different 
outcomes of HBV infection and spontaneous clearance 
[35]. On the contrary, a retrospective research in Japan 
enrolled 204 HBV-infected cases from 1999 to 2003, of 
those 161 people developed to chronic progressive liver 
Table 4: Association between IL-18 polymorphisms and LC and HCC risk
Model LC vs. Controls HCC vs. Controls LC vs. CHB HCC vs. CHB HCC vs. LC
Rs187238 OR
(95%CI)
P OR
(95%CI)
P OR
(95%CI)
P OR
(95%CI)
P OR
(95%CI)
P
Allele
C 1ref 0.10 1ref 0.95 1ref 0.11 1ref 0.98 1ref 0.12
G 0.73
(0.50-1.07)
0.99
(0.69-1.42)
1.37
(0.93-2.01)
1.004
  (0.67-1.51)
1.36
(0.92-2.00)
Codominant model
CC 1ref 1ref 1ref 1ref 1ref
CG 0.59
(0.38-0.91)
0.02 0.74
(0.48-1.13)
0.16 1.09
(0.70-1.70)
0.70 0.87
(0.55-1.37)
0.54 1.26 
(0.80-2.00)
0.32
GG 2.26
(0.43-11.8)
0.54 4.40
(0.94-20.7)
0.04 4.81
(1.03-22.6)
0.03 2.28
(0.47-12.91)
0.47 1.94
(0.64-5.91)
0.23
Dominant model
CC 1ref 0.04 1ref 0.02 1ref 0.32 1ref 0.75 1ref 0.19
CG+GG 0.64
(0.42-0.97)
0.85
(0.56-1.27)
1.24
(0.81-1.90)
0.93
(0.60-1.45)
1.33
(0.86-2.06)
Recessive model
CC+CG 1ref 0.44 1ref 0.03 1ref 0.03 1ref 0.44 1ref 0.26
GG 2.54
(0.49-13.2)
4.73
(1.01-22.1)
4.73
(1.01-22.1)
2.54
(0.49-13.2)
1.86
(0.61-5.63)
Rs1946518 OR
(95%CI)
P OR
(95%CI)
P OR
(95%CI)
P OR
(95%CI)
P OR
(95%CI)
P
Allele
G 1ref 0.53 1ref 0.85 1ref 0.95 1ref 0.70 1ref 0.66
T 0.92
(0.72-1.18)
0.98
(0.76-1.25)
1.01
(0.79-1.29)
0.95
(0.74-1.22)
1.06
(0.82-1.36)
Codominant model
GG 1ref 1ref 1ref 1ref 1ref
GT 0.85
(0.56-1.29)
0.44 0.91
(0.59-1.39)
0.66 0.80
(0.52-1.23)
0.31 0.75
(0.49-1.14)
0.17 0.92
(0.60-1.42)
0.72
TT 0.86
(0.53-1.40)
0.55 0.96
(0.58-1.56)
0.86 1.03
(0.62-1.70)
0.92 0.92
(0.56-1.52)
0.76 1.11
(0.68-1.81)
0.67
Dominant model
GG 1ref 0.42 1ref 0.70 1ref 0.49 1ref 0.27 1ref 0.68
GT+TT 0.85
(0.57-1.26)
0.92
(0.62-1.38)
0.87
(0.58-1.30)
0.80
(0.54-1.19)
1.09
(0.73-1.61)
Recessive model
GG+GT 1ref 0.84 1ref 0.94 1ref 0.42 1ref 0.60 1ref 0.78
TT 0.96
(0.64-1.44)
1.02
(0.68-1.53)
1.19
(0.78-1.80)
1.12
(0.74-1.70)
1.06
(0.71-1.60)
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odd ratio; 95%CI, 95% confidence interval.
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disease with 62 CHB patients, 52 LC patients, and 47 LCC 
patients [36]. A protect effect of -607AA genotype and 
-137C allele on the disease progression of HBV carriers 
was observed [36]. Rs187238C allele was related to HCC 
in codominant and dominant models and its C allele 
showed significantly lower promoter activities which may 
affect IL-18 production and further affect CHB progression 
[37]. However, several studies suggested reversed 
conclusions. Bao J et al. revealed rs187238 not rs1946518 
polymorphism may be a protective factor against HCC 
[38]. The genotype and allele frequencies of rs1946518 
polymorphism showed no significant differences between 
any two groups of healthy controls, CHB, and HCC groups 
[25]. A meta-analysis published in 2016, including eight 
Table 5: Association between IL-18 polymorphisms and LC and HCC risk adjusted by gender, age, 
smoking and drinking
Model LC vs. Controls HCC vs. Controls LC vs. CHB HCC vs. CHB HCC vs. LC
Rs187238 OR*
(95%CI*)
P* OR*
(95%CI*)
P* OR*
(95%CI*)
P* OR*
(95%CI*)
P* OR*
(95%CI*)
P*
Allele
C 1ref 0.51 1ref 0.82 1ref 0.04 1ref 0.78 1ref 0.23
G 0.85
(0.51-1.39)
1.05
(0.68-1.62)
1.60
(1.01-2.53)
1.06
(0.69-1.65)
1.29
(0.86-1.93)
Codominant model
CC 1ref 1ref 1ref 1ref 1ref
CG 0.74
(0.43-1.28)
0.28 0.70
(0.41-1.18)
0.18 1.31
(0.76-2.27)
0.33 0.98
(0.60-1.60)
0.92 1.16
(0.70-1.90)
0.57
GG 2.25
(0.27-18.47)
0.45 6.96
(1.24-39.0)
0.03 6.25
(1.09-35.8)
0.04 2.09
(0.34-
12.82)
0.42 2.38
(0.62-9.10)
0.20
Dominant model
CC 1ref 0.37 1ref 0.52 1ref 0.12 1ref 0.94 1ref 0.35
CG+GG 0.78
(0.46-1.33)
0.85
(0.52-1.40)
1.52
(0.90-2.57)
1.02
(0.63-1.65)
1.26
(0.78-2.02)
Recessive model
CC+CG 1ref 0.41 1ref 0.02 1ref 0.046 1ref 0.42   1ref 0.22
GG 2.41
(0.29-19.82)
7.64
(1.37-42.5)
5.91
(1.04-33.7)
2.10
(0.34-12.85)
2.32
(0.61-8.81)
Rs1946518 OR*
(95%CI*)
P* OR*
(95%CI*)
P* OR*
(95%CI*)
P* OR*
(95%CI*)
P* OR*
(95%CI*)
P*
Allele
G 1ref 0.73 1ref 0.56 1ref 0.37 1ref 0.72 1ref 0.78
T 1.06
(0.78-1.44)
0.91
(0.67-1.24)
0.87
(0.63-1.18)
0.95
(0.72-1.25)
1.04
(0.78-1.36)
Codominant model
GG 1ref 1ref 1ref 1ref 1ref
GT 0.95
(0.55-1.62)
0.84 0.75
(0.44-1.28)
0.29 0.59
(0.35-1.01)
0.05 0.72
(0.45-1.15)
0.17 1.15
(0.72-1.84)
0.55
TT 1.12
(0.60-2.07)
0.72 0.84
(0.45-1.54)
0.57 0.76
(0.41-1.42)
0.39 0.92
(0.53-1.58)
0.76 1.07
(0.63-1.83)
0.80
Dominant model
GG 1ref 0.99 1ref 0.32 1ref 0.09 1ref 0.27 1ref 0.60
GT+TT 1.002
(0.61-1.66)
0.78
(0.47-1.28)
0.64
(0.39-1.06)
0.78
(0.50-1.21)
1.12
(0.73-1.73)
Recessive model
GG+GT 1ref 0.57 1ref 0.97 1ref 0.79 1ref 0.58 1ref 0.93
TT 1.16
(0.70-1.93)
1.01
(0.61-1.67)
1.07
(0.64-1.80)
1.13
(0.72-1.78)
0.98
(0.63-1.54)
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odd ratio; 95%CI, 95% confidence interval; 
OR*, OR values adjusted by gender, age, smoking and drinking; P*, P values adjusted by gender, age, smoking and drinking.
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studies about rs187238 polymorphism and seven studies 
about rs1946518 polymorphism, provided an evidence that 
the two polymorphisms had no influence on the risk of 
HCC in general or specifically of HBV-positive HCC [26].
Different from the previous studies, we enrolled 
1000 people who were at different stages from health to 
HCC. The four groups did differ significantly in alcohol 
history and diabetes history. For LC patients carrying 
HBV, heavy alcohol consumption is a independent 
increased risk of HCC [39]. Lin CW et al. found in LC 
patients, the incidence of HCC was higher in patients with 
HBV infection and alcohol history than those with HBV 
infection or alcohol history alone [40]. Acetaldehyde, the 
ethanol metabolite, has carcinogenic characteristics by 
DNA binding [41]. Drinking-induced chronic oxidative 
stress and cytokine production could lead to LC and HCC 
development in the presence of chronic inflammation 
[42]. Alcohol could also promote HCC occurrence by 
deregulating the level of retinoic acid and S-adenosyl-L-
methionine, and activing the Wnt/β-catenin pathway [43]. 
Diabetes could alter the hepatic function and the structure 
of the hepatocytes in the diabetic rats model, possibly by 
increasing hepatic oxidative stress, attenuating antioxidant 
capacity and further impairing liver [44, 45]. Our results 
indicated rs187238 GG genotype increased the risk of 
HCC in healthy population and the risk of LC in CHB 
carriers, and rs187238 CG genotype decreased the risk 
of LC in health population. Epidemiological studies had 
demonstrated several risk factors for liver cancer including 
tobacco exposure, alcohol consumption, diabetes mellitus, 
HBV and HCV infection [46]. Though there is a significant 
difference in diabetes history between healthy controls and 
cases, researchers had different opinions about the impact 
of rs187238 and rs1946518 polymorphisms on diabetes 
[32, 47]. So we controlled for age, gender, smoking 
and alcohol consumption to minimize any possible 
confounding of results by these factors and finally found 
health people with GG genotype still had a higher risk of 
HCC and CHB patients carrying GG genotype still had a 
higher risk of LC. But no association between rs1946518 
polymorphism and HCC or LC risk was identified.
Our results should be interpreted with caution 
because of several limitations. Firstly, though we recruited 
1000 samples in this study, the sample size of each group 
was relative small which may restrict its detail subgroup 
analysis by the clinical index.. Secondly, considering 
we just controlled four factors (age, gender, smoking 
and alcohol consumption), other factors including 
Table 7: Analysis of IL-18 haplotype frequencies with the risk of LC and HCC adjusted by gender, 
age, smoking and drinking
HCC vs. 
Controls
HCC vs. LC HCC vs. CHB LC vs. Controls LC vs. CHB
Haplotypes OR*
(95% CI*)
P* OR*
(95% CI*)
P* OR*
(95% CI*)
P* OR*
(95% CI*)
P* OR*
(95% CI*)
P*
GT 1.01
(0.65–1.57)
0.96 1.28
(0.85–1.91)
0.24 1.55
(0.98–2.46)
0.06 0.85
(0.51–1.39)
0.51 1.06
(0.69–1.65)
0.78
CT 0.91
(0.66–1.25)
0.55 0.93
(0.70–1.24)
0.62 0.69
(0.50–0.96)
0.03 1.14
(0.83–1.56)
0.43 0.92
(0.69–1.23)
0.58
CG 1.09
(0.80–1.48)
0.59 0.95
(0.73–1.25)
0.74 1.14
(0.83–1.56)
0.43 0.95
(0.70–1.29)
0.73 1.05
(0.80–1.38)
0.72
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; GT, Grs187238Trs1946518; CT, Crs187238Trs1946518; CG, 
Crs187238Grs1946518; OR, odd ratio; 95%CI, 95% confidence interval.
Table 6: Analysis of IL-18 haplotype frequencies with the risk of LC and HCC
HCC vs. Controls HCC vs. LC HCC vs. CHB LC vs. Controls LC vs. CHB
Haplotypes OR
(95% CI)
P OR
(95% CI)
P OR
(95% CI)
P OR
(95% CI)
P OR
(95% CI)
P
GT 0.98
(0.68–1.40)
0.90 1.30
(0.90–1.87)
0.16 1.32
(0.91–1.92)
0.15 0.73
(0.49–1.07)
0.10 1.004
(0.67–1.50)
0.98
CT 0.99
(0.77–1.29)
0.96 0.94
(0.73–1.23)
0.67 0.88
(0.68–1.15)
0.36 1.05
(0.81–1.36)
0.71 0.94
(0.72–1.22)
0.63
CG 1.02
(0.79–1.30)
0.90 0.93
(0.73–1.19)
0.58 0.98
(0.77–1.27)
0.90 1.09
(0.85–1.39)
0.49 1.06
(0.82–1.36)
0.65
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; GT, Grs187238Trs1946518; CT, Crs187238Trs1946518; CG, 
Crs187238Grs1946518; OR, odd ratio; 95%CI, 95% confidence interval.
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environmental background, treatment protocols and living 
habits may cause some bias. Thirdly, all participants were 
all from Shaanxi Province, China, which may not stand 
for all the Chinese population. Lastly, the fundamental 
experiments should be further conducted to validate our 
results and explore the possible mechanism.
In conclusion, our research revealed that rs187238 
GG genotype increased the risk of HCC in healthy 
population and the risk of LC in CHB carriers. However, 
rs1946518 polymorphism had no impact on CHB-related 
liver diseases. These results indicated that IL-18 rs187238 
polymorphism may be involved in the progression of 
CHB-related diseases in Northwest Chinese population.
MATERIALS AND METHODS
Ethnics statement
This study was approved by the Ethics Committee 
of the Second Affiliated Hospital of Xi’an Jiaotong 
University (Xi’an, China). The research protocol was 
completed according to the approved guidelines.
Study population
For the current analysis, we established a case-
control study of 250 healthy controls, 250 CHB carriers, 
250 LC patients and 250 HCC patients. HBV infection 
was detected by ELISA method that requiring positivity 
of serum HBsAg and serum negativity for anti-HCV. 
LC patients and HCC patients were confirmed by 
pathological diagnosed. All the subjects were from the 
Second Affiliated Hospital of Xi’an Jiaotong University, 
and Xijing Hospital of Fourth Military Medical University, 
Xi’an, Shaanxi Province, China. Every participant 
was interviewed in-person including questions on age, 
demographics, ethnicity, height and weight, smoking and 
drinking habits, and medical history. Blood samples were 
collected after interview.
Genotyping assay
The samples were centrifugated and stored in −80°C 
freezers for long-term storage. The genomic DNA was 
extracted and concentrated by the method described in our 
previous studies [48, 49]. Two tag-SNPs (rs187238 and 
rs1946518) were selected in this study. SNP genotyping 
was performed by the Sequenom MassARRAY RS1000, 
and the primers were listed in Table 8. The data analyses 
were completed by Sequenom Type 4.0.
Statistical analyses
All the statistical analyses were completed using 
the SPSS software package (version 20.0; SPSS Inc., 
Chicago, IL, USA). HWE was examined by comparing 
expected and observed frequencies using Alrlquin 3.1 
program (L. Excoffier, CMPG, University of Bern, 
Switzerland). The genotype frequencies of observed 
values were compared with expected values obtained 
from HWE theory (p2+2pq+q2=1; p is the frequency of 
the wild-type allele and q is the frequency of the variant 
allele). Haplotype analysis was performed by PHASE v2.1 
software. The calculation was performed by χ2 test and 
the degree of freedom was 1 in the cases and controls. The 
significant difference in allele and genotype frequencies 
between cases and controls was determined by Pearson’s 
χ2 test. ORs and 95%CIs were calculated with and without 
adjustment for gender, age, smoking and drinking. We 
evaluated the risk in the dominant model (AA+ Aa vs. 
aa), the recessive model (aa vs. Aa+AA), and the allele 
model (a vs. A) respectively (A: the major allele, a: the 
minor allele). A two-sided P-value < 0.05 was considered 
statistically significant in all the tests.
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